BioNTech SE
NASDAQ:BNTX

Watchlist Manager
BioNTech SE Logo
BioNTech SE
NASDAQ:BNTX
Watchlist
Price: 113.13 USD 4.53% Market Closed
Market Cap: 27.3B USD
Have any thoughts about
BioNTech SE?
Write Note

Intrinsic Value

BNTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one BNTX stock under the Base Case scenario is 33.33 USD. Compared to the current market price of 113.13 USD, BioNTech SE is Overvalued by 71%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BNTX Intrinsic Value
33.33 USD
Overvaluation 71%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
BioNTech SE

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BNTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BNTX?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
BioNTech SE

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about BioNTech SE

Provide an overview of the primary business activities
of BioNTech SE.

What unique competitive advantages
does BioNTech SE hold over its rivals?

What risks and challenges
does BioNTech SE face in the near future?

Summarize the latest earnings call
of BioNTech SE.

What significant events have occurred
in BioNTech SE over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for BioNTech SE.

Provide P/S
for BioNTech SE.

Provide P/E
for BioNTech SE.

Provide P/OCF
for BioNTech SE.

Provide P/FCFE
for BioNTech SE.

Provide P/B
for BioNTech SE.

Provide EV/S
for BioNTech SE.

Provide EV/GP
for BioNTech SE.

Provide EV/EBITDA
for BioNTech SE.

Provide EV/EBIT
for BioNTech SE.

Provide EV/OCF
for BioNTech SE.

Provide EV/FCFF
for BioNTech SE.

Provide EV/IC
for BioNTech SE.

Show me price targets
for BioNTech SE made by professional analysts.

What are the Revenue projections
for BioNTech SE?

How accurate were the past Revenue estimates
for BioNTech SE?

What are the Net Income projections
for BioNTech SE?

How accurate were the past Net Income estimates
for BioNTech SE?

What are the EPS projections
for BioNTech SE?

How accurate were the past EPS estimates
for BioNTech SE?

What are the EBIT projections
for BioNTech SE?

How accurate were the past EBIT estimates
for BioNTech SE?

Compare the revenue forecasts
for BioNTech SE with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of BioNTech SE and its key competitors using the latest financial data.

Compare historical revenue growth rates
of BioNTech SE against its competitors.

Analyze the profit margins
(gross, operating, and net) of BioNTech SE compared to its peers.

Compare the P/E ratios
of BioNTech SE against its peers.

Discuss the investment returns and shareholder value creation
comparing BioNTech SE with its peers.

Analyze the financial leverage
of BioNTech SE compared to its main competitors.

Show all profitability ratios
for BioNTech SE.

Provide ROE
for BioNTech SE.

Provide ROA
for BioNTech SE.

Provide ROIC
for BioNTech SE.

Provide ROCE
for BioNTech SE.

Provide Gross Margin
for BioNTech SE.

Provide Operating Margin
for BioNTech SE.

Provide Net Margin
for BioNTech SE.

Provide FCF Margin
for BioNTech SE.

Show all solvency ratios
for BioNTech SE.

Provide D/E Ratio
for BioNTech SE.

Provide D/A Ratio
for BioNTech SE.

Provide Interest Coverage Ratio
for BioNTech SE.

Provide Altman Z-Score Ratio
for BioNTech SE.

Provide Quick Ratio
for BioNTech SE.

Provide Current Ratio
for BioNTech SE.

Provide Cash Ratio
for BioNTech SE.

What is the historical Revenue growth
over the last 5 years for BioNTech SE?

What is the historical Net Income growth
over the last 5 years for BioNTech SE?

What is the current Free Cash Flow
of BioNTech SE?

Discuss the annual earnings per share (EPS)
trend over the past five years for BioNTech SE.

Business Breakdown

BioNTech SE, founded in 2008 and headquartered in Mainz, Germany, is a pioneering biotechnology company that has rapidly garnered global attention for its innovative approach to vaccine development and personalized cancer therapies. Originally focused on harnessing the power of messenger RNA (mRNA) technology, BioNTech became a household name following its collaboration with Pfizer to develop one of the first COVID-19 vaccines. This partnership not only showcased the potential of mRNA technology in combatting infectious diseases but also underscored the company’s agility in responding to urgent global health challenges. With its robust pipeline of therapeutics spanning infectious diseases an...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
BioNTech SE

Current Assets 18.3B
Cash & Short-Term Investments 17.3B
Receivables 286.5m
Other Current Assets 699.4m
Non-Current Assets 4B
Long-Term Investments 1.4B
PP&E 1.1B
Intangibles 1.2B
Other Non-Current Assets 210.5m
Current Liabilities 2.4B
Accounts Payable 881.5m
Other Current Liabilities 1.5B
Non-Current Liabilities 739.7m
Long-Term Debt 219.3m
Other Non-Current Liabilities 520.4m
Efficiency

Earnings Waterfall
BioNTech SE

Revenue
2.7B EUR
Cost of Revenue
-396.2m EUR
Gross Profit
2.3B EUR
Operating Expenses
-3B EUR
Operating Income
-733.3m EUR
Other Expenses
228.9m EUR
Net Income
-504.4m EUR

Free Cash Flow Analysis
BioNTech SE

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q3 2024, BioNTech reported revenues of EUR 1.245 billion, a rise from EUR 895 million in Q3 2023, primarily driven by early COVID-19 vaccine approvals. The company posted a net income of EUR 198 million and diluted EPS of EUR 0.81. Despite robust revenues, BioNTech anticipates a loss for the full year and has adjusted SG&A expense guidance down to EUR 600-700 million, reducing capital expenditure guidance to EUR 300-400 million. Their oncology pipeline, highlighted by the promising BNT327 antibody, is poised for multiple product launches by 2030, demonstrating a 74% objective response rate in trials for triple-negative breast cancer.

What is Earnings Call?
Fundamental Scores

BNTX Profitability Score
Profitability Due Diligence

BioNTech SE's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Year Average ROIC
Positive Free Cash Flow
Positive Gross Profit
62/100
Profitability
Score

BioNTech SE's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

BNTX Solvency Score
Solvency Due Diligence

BioNTech SE's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
74/100
Solvency
Score

BioNTech SE's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BNTX Price Targets Summary
BioNTech SE

Wall Street analysts forecast BNTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BNTX is 138.68 USD with a low forecast of 100.23 USD and a high forecast of 179.55 USD.

Lowest
Price Target
100.23 USD
11% Downside
Average
Price Target
138.68 USD
23% Upside
Highest
Price Target
179.55 USD
59% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BNTX?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BNTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

BNTX News

Other Videos

Profile

BioNTech SE Logo
BioNTech SE

Country

Germany

Industry

Biotechnology

Market Cap

26.9B USD

Dividend Yield

0%

Description

BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 3,082 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The company develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Contact

RHEINLAND-PFALZ
Mainz
An der Goldgrube 12
+4949613190840.0
biontech.de

IPO

2019-10-10

Employees

3 082

Officers

Co-Founder, CEO & Chair of the Management Board
Dr. Ugur Sahin M.D.
Co-Founder, Chief Medical Officer & Member of Management Board
Dr. Ozlem Tureci M.D.
CFO & Member of Management Board
Mr. Jens H. Holstein
MD, COO & Member of Management Board
Dr. Sierk Poetting Ph.D.
Chief Strategy Officer, MD & Member of Management Board
Mr. Ryan Richardson
Chief Legal & Business Officer & Member of the Management Board
Dr. James Timothy Patrick Ryan Ph.D.
Show More
Executive Officer
Mr. Sean Marett
Senior Vice President of Corporate Development & Strategy
Mr. Zach Taylor
Senior VP & External Consultant for RNA Protein Replacement Therapies
Dr. Katalin Kariko Ph.D.
Senior Vice President of Operations
Dr. Oliver Henning Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one BNTX stock?

The intrinsic value of one BNTX stock under the Base Case scenario is 33.33 USD.

Is BNTX stock undervalued or overvalued?

Compared to the current market price of 113.13 USD, BioNTech SE is Overvalued by 71%.

Back to Top